MetaVia Inc. operates as a clinical-stage biotechnology company. The Company focuses on developing dual oxyntomodulin (OXM) analog agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). MetaVia serves customers worldwide.

Current Report (Form 8-K | Period ending 2024-11-29)

Current Report (Form 8-K | Period ending 2024-11-15)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

MetaVia (MTVA US)

Current Report (Form 8-K | Period ending 2024-11-29)

Current Report (Form 8-K | Period ending 2024-11-15)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-11-07)

Current Report (Form 8-K | Period ending 2024-11-04)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)